comprehensive -WSS

comprehensive

author：hotspot 2025-09-03 03:39:46 - browse：5571

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Shionogi licenses Pompe disease therapy from Maze Therapeutics

leisure time

WSS

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

3 questions for the future of Biden's cancer moonshot

Bird flu outbreak in cows is latest avian flu curveball

Chemotherapy drug shortage eases slightly but still widespread

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Study: Adult vaccinations pay for themselves in societal benefits

hotspot

comprehensive

leisure time

In age of alternative facts, a scholarly course on calling out crap

Stroke deaths set to near 10 million globally by 2050

ChatGPT in medicine: STAT answers readers' burning questions

Chan Zuckerberg Biohub Chicago to focus on inflammation

Novavax promises a turnaround & Lilly roils the obesity market

3 questions for the future of Biden's cancer moonshot

Anesthesiologist group: stop taking Ozempic before surgery

Sanofi strikes deal with Novavax, boosting the vaccine maker

Affirmative action in medical school literally saved lives

Physician executives need more than on

explore

Study: Adult vaccinations pay for themselves in societal benefits

How to improve immunocompromised access to mAb treatments

Analysis of telehealth claims data suggest service duplication

Why Charlie Gard's case is so disturbing to Americans

Researchers on aging grapple with how to calculate biological age

Brain worms: The science behind RFK Jr.'s parasitic infection

knowledge

leisure time

entertainment

leisure time